37,649 Shares in Ionis Pharmaceuticals, Inc. $IONS Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 37,649 shares of the company’s stock, valued at approximately $1,488,000.

Other hedge funds have also recently modified their holdings of the company. Signaturefd LLC lifted its holdings in shares of Ionis Pharmaceuticals by 45.6% during the first quarter. Signaturefd LLC now owns 1,382 shares of the company’s stock worth $42,000 after purchasing an additional 433 shares during the period. Parallel Advisors LLC lifted its holdings in shares of Ionis Pharmaceuticals by 151.3% during the second quarter. Parallel Advisors LLC now owns 1,872 shares of the company’s stock worth $74,000 after purchasing an additional 1,127 shares during the period. Ancora Advisors LLC purchased a new position in Ionis Pharmaceuticals in the first quarter worth $60,000. CWM LLC raised its position in Ionis Pharmaceuticals by 18.7% in the first quarter. CWM LLC now owns 2,435 shares of the company’s stock worth $73,000 after acquiring an additional 384 shares in the last quarter. Finally, GF Fund Management CO. LTD. raised its position in Ionis Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 4,042 shares of the company’s stock worth $122,000 after acquiring an additional 727 shares in the last quarter. 93.86% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Barclays increased their price objective on Ionis Pharmaceuticals from $80.00 to $95.00 and gave the stock an “overweight” rating in a research report on Thursday. TD Cowen increased their price objective on Ionis Pharmaceuticals from $59.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, October 8th. Citigroup increased their price objective on Ionis Pharmaceuticals from $69.00 to $84.00 and gave the stock a “buy” rating in a research report on Wednesday, September 3rd. Finally, Oppenheimer increased their price objective on Ionis Pharmaceuticals from $84.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $83.05.

Insider Activity

In related news, EVP Brian Birchler sold 12,425 shares of Ionis Pharmaceuticals stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $72.23, for a total transaction of $897,457.75. Following the completion of the sale, the executive vice president owned 56,826 shares in the company, valued at approximately $4,104,541.98. This trade represents a 17.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Brett P. Monia sold 437 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $69.26, for a total value of $30,266.62. Following the sale, the chief executive officer owned 179,572 shares of the company’s stock, valued at approximately $12,437,156.72. This represents a 0.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 778,221 shares of company stock worth $48,020,524 in the last quarter. Corporate insiders own 2.60% of the company’s stock.

Ionis Pharmaceuticals Trading Up 0.2%

NASDAQ:IONS opened at $74.30 on Monday. The company has a market capitalization of $12.03 billion, a PE ratio of -43.96 and a beta of 0.33. The company has a quick ratio of 2.86, a current ratio of 2.87 and a debt-to-equity ratio of 0.99. Ionis Pharmaceuticals, Inc. has a 52-week low of $23.95 and a 52-week high of $75.49. The stock has a fifty day simple moving average of $63.97 and a 200-day simple moving average of $46.78.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.35. The business had revenue of $157.00 million during the quarter, compared to the consensus estimate of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 26.45%.The business’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.95) EPS. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.